Pre-Conference Workshops

Workshop A — FDA 101: A Guide to Agency Structure, Jurisdiction, Regulation, and Applicable Laws

Mar 2021

Speakers

Christopher Mikson
Partner
DLA Piper LLP (Washington, DC)

Day 1

8:15
Co-Chairs’ Opening Remarks
8:30
Understanding the Relevance of New FDA Initiatives and Policies and How They May Redefine the Life Sciences Industry in the Aftermath of COVID-19
9:15

THE PRE-APPROVAL AND APPROVAL PROCESS

Navigating the Approval Process for Drugs and Biologics
10:15
Break
10:30

Review and Approval

Exploring FDA’s Expedited Review and Approval Programs: Applicability and Eligibility
11:45
1:1 Networking Break
11:55
Lunch Break
12:45
Appreciating the Nuances of the Approval Process for Controlled Substances
1:30
Clarifying the Clinical Trial Process for Drugs and Biologics
2:30
Break
3:00

IP OVERVIEW FOR DRUGS AND BIOLOGICS: HATCH-WAXMAN; BPCIA; TRADEMARKS; AND MORE

Part 1 – Patents and Related IP Protections and Mechanisms
3:45

IP OVERVIEW FOR DRUGS AND BIOLOGICS: HATCH-WAXMAN; BPCIA; TRADEMARKS; AND MORE

Part 2 – Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry
5:00
Drugs and Biologics Labeling: Appreciating the Importance of the Final Step of the Approval Process
5:45
Conference Adjourns to Day 2 – 30-minute Meet and Greet with Speakers

Day 2

8:30
Co-Chairs’ Opening Remarks and Recap of Day 1
8:45

POST APPROVAL

cGMPs: Discovering the Unique Role of Current Good Manufacturing Practices (“cGMPs”) in the Post Approval Process
9:45
Part 1 – Drug and Biologics Advertising and Promotion 101
10:30
Break
11:00
Part 2 – Exploring the Subtleties and Safe Zones of Off-Label Communications
11:45
Preparing for the Worst: Adverse Events Monitoring, Pharmacovigilance, Risk Management, and Recalls
12:45
Understanding the Scope of FDA Enforcement Authority and Actions
1:45
Main Conference Ends

Post-Conference Workshop

Workshop C — Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group

Mar 2021

Speakers

Jonathan B. Roses
Counsel
Wolf, Greenfield & Sacks, P.C. (Boston, MA)

Emily R. Whelan
Partner
WilmerHale (Boston, MA)

Day 1

8:15
Co-Chairs’ Opening Remarks

Kurt R. Karst
Partner
Hyman, Phelps & McNamara, P.C. (Washington, DC)

Torrey Cope
Partner
Sidley Austin LLP (Washington, DC)

8:30
Understanding the Relevance of New FDA Initiatives and Policies and How They May Redefine the Life Sciences Industry in the Aftermath of COVID-19

Kurt R. Karst
Partner
Hyman, Phelps & McNamara, P.C. (Washington, DC)

Torrey Cope
Partner
Sidley Austin LLP (Washington, DC)

The COVID-19 Pandemic has impacted thousands of businesses and organizations around the world. This opening session will focus on the actions of the U.S. Food and Drug Administration to protect the public to ensure the public has access to safe food and medical supplies, as well as its impact on the pharmaceutical and biologics industries.

9:15

THE PRE-APPROVAL AND APPROVAL PROCESS

Navigating the Approval Process for Drugs and Biologics

Kinsey S. Reagan
Partner
Kleinfeld, Kaplan and Becker, LLP (Washington, DC)

Innovator Products: New Drug Applications and Biologic License Applications

The Drug Review Process

  • Reviewing the fundamentals of applications; from submission, through filing and beyond
  • Making sense of PDUFA Goals, fast track, break through status, and other process enhancements
  • Use of administrative appeals

Rx Drugs (Small Molecules)

  • Understanding the difference between “new drugs” and other drugs
  • Examining the research, development, and approval process for new drugs
  • Dissecting the investigational new drug application (IND) vs. the new drug application (NDA)

Biological Products (Large Molecules)

  • What are biological products in relation to traditional drugs?
  • Deciphering the biologics license application (BLA)
  • How do the research, development, and approval process for biological products differ from the process for new drugs?
  • Exploring key similarities and differences between the drug and biological product schemes

NDAs and BLAs

  • Differentiating between 505(b)(1)s, 505(b)(2)s, and BLAs
  • Identifying applications for fixed-dose combination drugs
  • Distinguishing complex molecules regulated through NDAs from small molecules
  • Examining standards for approvals
  • REMS

OTC Products

  • Understanding the concept of “OTC” (OTC-ness)
  • Examining the OTC Review and monographs
    • Differences between approved and monographed OTC drug products
  • Understanding How FDARA and the 21st Century Cures Act are impacting drug approvals through new evidentiary requirements

10:15
Break
10:30

Review and Approval

Exploring FDA’s Expedited Review and Approval Programs: Applicability and Eligibility

Denise Esposito
Partner
Covington & Burling LLP (Washington, DC)

  • Distinguishing among the different FDA programs for expedited review and approval of drug products
  • Evaluating the criteria for eligibility, benefits, and limitations of each program
  • Understanding accelerated approval, surrogate and intermediate clinical endpoints
  • Assessing the breakthrough therapy, regenerative medicine advance therapy (RMAT), and fast track designation programs
  • Reviewing priority review
  • Factoring expedited programs into your drug development strategy

Case Study: Expedited Approval Case Study: Chasing the COVID-19 Vaccine

This case study will focus on the expedited approval process and other related health submissions to further access a COVID-10 vaccine for Americans. Experts will also identify any legislation that is being used to support the approval process.

11:45
1:1 Networking Break
11:55
Lunch Break
12:45
Appreciating the Nuances of the Approval Process for Controlled Substances

Lynn Mehler
Partner
Hogan Lovells (Washington, DC)

  • Defining the term “controlled substance”?
  • Reviewing the scheduling process for both approval as well as post-marketing approval with both the DEA and FDA
  • Discussing the proper steps for companies who incorporate CBD’s into their products
  • What clinical trial lab work is necessary to demonstrate to the proper agencies?
  • Exploring state regulations which exist when working with controlled substances
  • Implementing the manufacturing quotas which exist for these products

1:30
Clarifying the Clinical Trial Process for Drugs and Biologics

Maureen Bennett
Partner, Life Sciences
Co-leader for the Firm’s Health Care & Life Sciences Practice

Jones Day LLP (Boston, MA)

  • Overview of clinical trials and how they are used (including different phases)
  • Identifying the different parties involved (sponsors, investigators, CROs, etc.)
  • Understanding human research protection (ICF, IRB)
  • Enforcement
  • Review of the “Right to Try” laws and their requirements during the clinical trials process

2:30
Break
3:00

IP OVERVIEW FOR DRUGS AND BIOLOGICS: HATCH-WAXMAN; BPCIA; TRADEMARKS; AND MORE

Part 1 – Patents and Related IP Protections and Mechanisms

Karin Hessler
Assistant General Counsel
Association for Accessible Medicines LLP (Washington, DC)

Chad Landmon
Partner
Axinn, Veltrop & Harkrider LLP (Washington, DC)

Patent Protection for Drugs and Biologics

  • Summarizing the patenting process for drugs and biologics
  • Strategies for building patent protection for drugs and biologics
  • Applying for and achieving extension of patent term for time spent in the drug approval process
    • Patent Term Extension (“PTE”)
    • Patent Term Adjustment (“PTA”)
  • Reviewing the 271(e)(1) “safe harbor” provision
  • Distinguishing the patenting process for drugs from that of biologics
  • Identifying the respective roles of the FDA and the PTO in the protection of drugs and biological products Trademarks
  • Overview of selecting a brand name for a proposed drug product
  • Roles of the USPTO and FDA in the drug naming process
  • Identifying the PTO and FDA clearances necessary for trade name/trademark approval on your product
  • How does the branding process work for your product

3:45

IP OVERVIEW FOR DRUGS AND BIOLOGICS: HATCH-WAXMAN; BPCIA; TRADEMARKS; AND MORE

Part 2 – Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry

Bryan C. Diner
Partner
Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington, DC)

Adam L. Perlman
Partner
Latham & Watkins LLP (Washington, DC)

Drugs

  • Overview of Hatch-Waxman and reforms
    • 30-month stay; patent extensions; ANDA filer exclusivity (180 day)
  • Comparing the NDA, 505(b)(2), and ANDA (Abbreviated New Drug Application) drug approval routes
    • Reviewing fundamentals of applications
  • Exploring the ANDA Paragraph IV Certification, and response to Notice Letters
  • Examining ANDA Standards for approval and the concepts of sameness and bioequivalence
  • Special considerations: local acting drugs, labeling carve outs and other nuances
    • Understanding the role of the Orange Book in the drug approval process
    • Listings, de-listings and use codes
  • Market exclusivities and protection
  • Identifying the different types of exclusivities
    • Regulatory exclusivity (FDA)/(data) exclusivity
  • NCE (new chemical entity)
    • 5 years data exclusivity
  • Indication (new indication or use)
    • 3 years marketing exclusivity
  • NDF (new dosage formulation)
  • ODE (orphan drug exclusivity)
  • PED (pediatric exclusivity)

Biologics

  • Overview of biosimilar legislation and regulations, i.e., Biologics Price Competition and Innovation Act of 2009 (BPCIA)
  • Understanding the rationale for safety and efficacy concerns surrounding second generation biologics
  • Exploring the concepts of “biosimilarity” or “interchangeability”
  • FDA rule-making and guidance relative to biosimilars
  • Other points for consideration: substitution, naming, patents, and additional nuances
  • Examining biosimilar exclusivities
  • “Shall we dance” — weighing the pros and cons of participating in the patent dance
  • Deciding when to provide notice of commercial marketing

5:00
Drugs and Biologics Labeling: Appreciating the Importance of the Final Step of the Approval Process

Seth A. Mailhot
Partner
Husch Blackwell LLP (Washington, DC)

The labeling of the drug/biologic is the final stage of the approval process. The label controls what you can do post-approval and as such it is the point of transition between the approval process and post-approval world.

  • Labeling overview: key regulatory requirements, information, and contents
  • Exploring the review process for labeling
  • Incorporating clinical trial data on the label
  • Appreciating the influence of final labeling on the scope of postmarket activities
  • Amending labeling post-market
  • Using labeling as a defense in products liability litigation
  • Exploring label carve outs
  • Discussing the requirements for skinny and narrow labeling

5:45
Conference Adjourns to Day 2 – 30-minute Meet and Greet with Speakers

Day 2

8:30
Co-Chairs’ Opening Remarks and Recap of Day 1

Kurt R. Karst
Partner
Hyman, Phelps & McNamara, P.C. (Washington, DC)

Torrey Cope
Partner
Sidley Austin LLP (Washington, DC)

8:45

POST APPROVAL

cGMPs: Discovering the Unique Role of Current Good Manufacturing Practices (“cGMPs”) in the Post Approval Process

Kathleen M. Sanzo
Partner
Morgan, Lewis & Bockius LLP (Washington, DC)

  • Examining cGMPs (current Good Manufacturing Practices) and the scope of their importance in pharmaceutical/biological product commercialization
  • Factoring cGMPs into the scope of the FDA’s authority
  • Exploring the scope of the FDA’s cGMP Initiative and the concept of “risk-based” cGMPs
  • Conducting laboratory investigations in relation to cGMPs
  • Understanding the influence of cGMPs in products liability litigation
  • Evaluating the costs and impact of enforcement actions Advertising, Promotions, and Related First Amendment Concerns

9:45
Part 1 – Drug and Biologics Advertising and Promotion 101

Marc J. Scheineson, Esq.
Partner
Alston & Bird LLP (Washington, DC)

  • Overview of laws and regulations controlling the advertising, marketing, and promotion of prescription drugs and biologics
    • 21 CFR Sections 202.1, 352(n), 314.81(b)(3); Section 352(n) of FD&CA
    • Guidance documents
  • Exploring the role of DDMAC (Division of Drug Marketing, Advertising and Communications)
    • What duties and responsibilities is DDMAC charged with?
    • What are its enforcement capabilities and jurisdiction?
  • Identifying the role of the FTC in the advertising and promotion of drugs
    • SEC?
  • Advertising requirements for prescription v. nonprescription products
  • Reviewing the steps which DDMAC takes for the review of launch campaigns and promotional materials
    • Overview of the promotional materials submission and review process
  • What constitutes a launch?
  • What defines an advertisement?
    • What information must a drug advertisement include?
  • Exploring the role of the label in advertising

10:30
Break
11:00
Part 2 – Exploring the Subtleties and Safe Zones of Off-Label Communications

Joel Kurtzberg
Partner
Cahill Gordon and Reindel LLP (New York, NY)

  • Clarifying FDA’s current position on First Amendment and off-label promotion
    • The 21st Century Cures Act
    • FDAMA 114
  • What to expect concerning proposed legislation, rules changes and Citizen Petitions
  • Cases and controversies: state AG actions and private tort claims

11:45
Preparing for the Worst: Adverse Events Monitoring, Pharmacovigilance, Risk Management, and Recalls

Stephanie Philbin
Partner
Goodwin Procter LLP (Washington, D.C.)

  • What is pharmacovigilance?
  • How pharmacovigilance uses adverse event reports
    • Direct versus indirect reports
    • Causality assessments
    • Labeling changes
    • Pre-and post-market ADE reporting requirements
    • How regulatory agencies use ADE reports
  • Exploring protocols for Risk Evaluation and Minimization Strategies (REMS)
  • Understanding the role of risk evaluation in the approval process
  • Identifying risk minimization tools
  • Enforcing ADE reporting and REMS requirements
  • Examining the relevance to product liability risks, including innovator and co-promoter liability risks
  • What is the FDA’s recall and oversight authority (overview of 21 CFR Part 7)?
    • Guidance versus regulation
    • Market withdrawals and stock recoveries
    • Voluntary recalls versus mandatory recalls
  • Interaction between recalls and corrective and preventive action

12:45
Understanding the Scope of FDA Enforcement Authority and Actions

Bryant M. Godfrey
Counsel
Arnold & Porter (Washington, DC)

Chalana N. Damron
Counsel
Crowell & Moring

  • Enforcement overview — Identifying the players and their positions
    • Investigations, enforcement, litigation, and defenses
  • Understanding potential punishments, including civil seizure, injunction, civil money penalties, and criminal prosecutions
  • Exploring FDA compliance and enforcement mechanisms
    • Inspections
  • For cause inspections vs. routine inspections
  • Communication with the FDA during inspections
    • EIRs
    • Form FDA 483 observations
    • Untitled and Warning Letters
  • Related to inspections
  • Resulting from non-inspection data or information
  • Examining enforcement actions related to digital advertising and social media

1:45
Main Conference Ends

Workshop A — FDA 101: A Guide to Agency Structure, Jurisdiction, Regulation, and Applicable Laws

Mar 2021

Christopher Mikson
Partner
DLA Piper LLP (Washington, DC)

What is it about?

+ 1 HOUR ETHICS Bonus

This workshop, provides a basic overview of FDA regulations and will prepare you for the more in-depth discussions that will take place throughout the conference. Topics addressed during this workshop will set the stage for the main conference by helping you thoroughly comprehend the structure of FDA and obtain a basic understanding of the pre-approval, approval, and post-approval processes. This session also provides a built-in hour of ethics credit. Topics of discussion will include:

  • Examining the FDA’s structure, authority, and organization
  • The 3 major FDA centers and their roles
    • CDER (Drug); – CBER (Biologics);
    • CDRH (Device)
  • Reviewing major FDA regulations and applicable laws
  • Defining drugs, biologics, and devices
  • Understanding the role of labeling with respect to these definitions
  • Differentiating types of drug applications (INDs, NDAs, and ANDAs)
  • Exploring the clinical trials process
  • Investigating biological products and biosimilars
  • Evaluating post-market dilemmas and enforcement
  • Understanding recalls and withdrawals
  • Examining recent developments at FDA
  • FDA’s policies and procedures
  • Administrative Procedures Act
  • Working with the FDA through formal and informal dispute resolution mechanisms
  • Analyzing ethical dilemmas that may occur throughout various stages of interaction with the FDA, including the approval process related to the disclosure of adverse information

Workshop B — Medical Devices, Combination Products, and Companion Diagnostics Boot Camp: A Review of FDA Guidelines and Regulations

Mar 2021

Neil O’Flaherty
Partner
Amin Talati Wasserman LLP (Chicago, IL)

What is it about?

This workshop will provide an introduction and in-depth overview of medical devices, combination products, and companion diagnostics as well as the FDA regulations which govern these products.

Topics of discussion will include:

Medical Devices

  • Reviewing the history of FDA device regulations
  • Examining the basics of device classification and the FDA’s review process
  • Analyzing the clinical trials process for medical devices
  • Assessing strategies to obtain clinical data
  • Determining premarket approvals
  • Exploring the 510(k) clearance process
  • Discussing key regulatory requirements, information, and concepts

Combination Products

  • Defining the requirements for combination product classification and approval
  • Selecting the proper regulatory pathway
  • Exploring the Request for designation (RFD) process and the newly-created pre-RFD process
  • Determining the role of the Combination Product Policy Council and agencies regulating combination products
  • Examining existing cGMP’s for combination products

Companion Diagnostics

  • Exploring the regulations of laboratory developed tests (LDTs)
  • Examining the approval process for in vitro diagnostic devices (IVDs) and Next Generation Sequencing (NGS) IVDs
  • Utilizing companion diagnostics via smart technologies

Workshop C — Hatch-Waxman and BPCIA in the Trenches: Exclusivity and Bioequivalency Working Group

Mar 2021

Jonathan B. Roses
Counsel
Wolf, Greenfield & Sacks, P.C. (Boston, MA)

Emily R. Whelan
Partner
WilmerHale (Boston, MA)

What is it about?

This workshop will build upon the content covered during the main conference on the regulatory and IP interplay in the Hatch-Waxman and BPCIA schematics. Our workshop leaders will in a step by-step manner:

  • Deconstruct complex exclusivity disputes
  • Analyze FDA’s and the disputing parties’ various (and sometimes evolving) positions on exclusivity
  • Explore bioequivalency conundrums

Relevant court decisions will also be analyzed and their practical and future effects discussed. Workshop attendees will have the opportunity to understand how the exclusivity “rules of the road” are applied in a real-world case.